Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AEMD

AEMD - Aethlon Medical Inc Stock Price, Fair Value and News

1.71USD+0.01 (+0.59%)Market Closed
Watchlist

Market Summary

USD1.71+0.01
Market Closed
0.59%

AEMD Stock Price

View Fullscreen

AEMD RSI Chart

AEMD Valuation

Market Cap

4.5M

Price/Earnings (Trailing)

-0.37

Price/Sales (Trailing)

1.19

Price/Free Cashflow

-0.42

AEMD Price/Sales (Trailing)

AEMD Profitability

Return on Equity

-160.94%

Return on Assets

-117.37%

Free Cashflow Yield

-240.32%

AEMD Fundamentals

AEMD Revenue

Revenue (TTM)

3.7M

Rev. Growth (Yr)

-8.37%

Rev. Growth (Qtr)

-41%

AEMD Earnings

Earnings (TTM)

-12.2M

Earnings Growth (Yr)

-21.63%

Earnings Growth (Qtr)

-14.23%

Breaking Down AEMD Revenue

Last 7 days

-4.0%

Last 30 days

-15.7%

Last 90 days

2.5%

Trailing 12 Months

215.1%

How does AEMD drawdown profile look like?

AEMD Financial Health

Current Ratio

3.93

AEMD Investor Care

Shares Dilution (1Y)

14.08%

Diluted EPS (TTM)

-5.02

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20233.5M3.7M3.8M3.7M
20222.6M2.9M3.2M3.5M
20212.6M2.7M2.6M2.5M
20202.7M2.7M2.6M2.6M
20192.2M2.3M2.7M2.7M
20181.9M2.0M2.0M2.6M
20172.2M1.9M1.8M1.5M
20162.3M2.3M2.4M2.4M
20151.6M1.7M1.8M2.1M
20141.6M1.7M1.7M1.2M
20131.9M1.7M1.6M1.7M
20121.6M1.7M1.9M1.9M
20111.1M1.3M1.2M1.3M
20100000

Tracking the Latest Insider Buys and Sells of Aethlon Medical Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 29, 2023
broenniman edward g
sold (taxes)
-2,546
2.19
-1,163
-
Dec 29, 2023
shah chetan
sold (taxes)
-2,546
2.19
-1,163
-
Dec 29, 2023
gikakis nicolas
sold (taxes)
-4,279
2.19
-1,954
-
Sep 29, 2023
gikakis nicolas
sold (taxes)
-4,494
0.23
-19,541
-
Sep 29, 2023
broenniman edward g
sold (taxes)
-2,674
0.23
-11,628
-
Sep 29, 2023
shah chetan
sold (taxes)
-2,674
0.23
-11,628
-
Jul 03, 2023
gikakis nicolas
acquired
-
-
195,414
-
Jun 30, 2023
broenniman edward g
sold (taxes)
-4,186
0.36
-11,628
-
Jun 30, 2023
shah chetan
sold (taxes)
-4,186
0.36
-11,628
-
Apr 28, 2023
rossetti angela
acquired
-
-
116,279
-

1–10 of 50

Which funds bought or sold AEMD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
STATE STREET CORP
sold off
-100
-8,350
-
-%
Feb 14, 2024
Royal Bank of Canada
sold off
-100
-
-
-%
Feb 14, 2024
VANGUARD GROUP INC
new
-
46,481
46,481
-%
Feb 14, 2024
VANGUARD GROUP INC
sold off
-100
-43,050
-
-%
Feb 14, 2024
TWO SIGMA INVESTMENTS, LP
sold off
-100
-9,743
-
-%
Feb 14, 2024
BARTLETT & CO. WEALTH MANAGEMENT LLC
new
-
57.00
57.00
-%
Feb 14, 2024
BARTLETT & CO. WEALTH MANAGEMENT LLC
sold off
-100
-60.00
-
-%
Feb 14, 2024
GROUP ONE TRADING, L.P.
new
-
2,886
2,886
-%

1–10 of 43

Are Funds Buying or Selling AEMD?

Are funds buying AEMD calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AEMD
No. of Funds

Unveiling Aethlon Medical Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 13, 2022
empery asset management, lp
0.68%
105,000
SC 13G/A
Jun 15, 2021
empery asset management, lp
9.82%
1,388,079
SC 13G
Feb 22, 2021
iroquois capital management, llc
0.86%
104,572
SC 13G/A
Jan 29, 2021
intracoastal capital, llc
1.5%
179,116
SC 13G/A
Jan 13, 2021
empery asset management, lp
4.99%
825,020
SC 13G
Feb 14, 2020
iroquois capital management, llc
6.3%
110,701
SC 13G/A
Feb 11, 2020
intracoastal capital, llc
9.99%
324,082
SC 13G/A
Jan 27, 2020
empery asset management, lp
4.99%
30,545
SC 13G/A
Jan 27, 2020
empery asset management, lp
7.73%
506,700
SC 13G
Jan 24, 2020
armistice capital, llc
3.8%
315,648
SC 13G

Recent SEC filings of Aethlon Medical Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
8-K
Current Report
Feb 14, 2024
10-Q
Quarterly Report
Jan 02, 2024
4
Insider Trading
Jan 02, 2024
4
Insider Trading
Jan 02, 2024
4
Insider Trading
Dec 22, 2023
8-K/A
Current Report
Nov 27, 2023
8-K
Current Report

Peers (Alternatives to Aethlon Medical Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
207.1B
40.1B
0.08% 5.41%
36.19
5.16
-8.12% -17.45%
70.3B
19.5B
1.90% -2.48%
56
3.61
4.02% -22.04%
24.2B
3.8B
13.67% -2.23%
66.83
6.37
-1.48% -28.97%
21.3B
14.9B
3.05% 1.38%
8.03
1.43
2.01% 209.17%
MID-CAP
10.0B
12.7B
2.56% -12.12%
22.51
0.79
0.68% -30.25%
9.9B
2.7B
6.89% -27.73%
-15.59
3.72
-4.68% 82.43%
9.3B
3.5B
8.76% 25.90%
32.84
2.68
4.97% 18.89%
7.1B
3.9B
-8.15% -6.44%
-32.48
1.81
-2.62% 73.16%
3.5B
342.6M
-1.40% 20.18%
-287.71
10.08
42.19% 84.12%
2.6B
6.6B
-4.32% -4.67%
13.13
0.4
2.61% 0.52%
SMALL-CAP
1.0B
3.1B
8.08% -63.68%
-2.41
0.33
7.95% -543.98%
363.5M
163.3M
8.18% -20.52%
-14.79
2.23
7.14% -56.09%
238.7M
329.5M
3.17% -52.24%
-16.91
0.72
0.49% 64.22%
74.1M
50.3M
4.50% -30.54%
-4.89
1.47
3.23% 20.81%
4.5M
3.7M
-15.66% 215.09%
-0.37
1.19
5.77% 8.23%

Aethlon Medical Inc News

Latest updates
Investing.com21 Feb 202401:24 pm
Seeking Alpha13 Feb 202410:35 pm

Aethlon Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-41.0%6691,1339779717301,004844968433649583792625656564749610762608748587
Operating Expenses12.3%3,5673,1753,4083,0522,8503,6652,9063,7992,5452,1412,2302,2993,0691,7711,4101,9921,2901,7021,5961,6711,964
  S&GA Expenses15.1%9798511,3088281,0711,5481,0321,0271,112686630573921555409550274342383272215
Interest Expenses------------------11.0072.00--
Net Income-14.2%-3,466-3,034-3,282-2,466-2,849-3,807-2,906-3,784-2,525-2,008-2,098-2,259-2,444-1,771-1,411-1,781-819-1,706-2,067-1,634-2,013
Net Income Margin-7.0%-3.27*-3.05*-3.37*-3.39*-3.76*-4.01*-3.88*-3.95*-3.62*-3.33*-3.23*-2.99*-2.86*--------
Free Cashflow12.0%-2,386-2,710-2,712-2,958-2,102-3,617-2,770-3,311-2,776-1,918-2,110-2,243-2,228--------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-18.6%10,43712,82815,80117,50920,72423,04717,13219,41821,91623,87425,86710,66912,67015,05616,42710,3884,6821,2822,9334,1234,951
  Current Assets-21.3%8,24910,48713,30815,09118,17220,50415,89418,15721,21023,56925,54810,35212,32214,75216,09510,0414,3069002,6444,0384,860
    Cash Equivalents-20.8%8,06010,17612,89814,62017,50019,60414,92217,16020,39523,22525,1729,90812,17814,47315,7229,6054,0597862,4923,8284,825
  Net PPE-7.2%1,1141,2001,2841,1441,2121,1394524412542141881611671461501401451256.006.0010.00
Liabilities12.6%2,8252,5092,6922,4453,4453,1792,2122,4271,3571,3631,3691,3751,2361,4901,2401,1108781,2611,9151,8241,781
  Current Liabilities22.8%2,1011,7111,8221,5052,4362,1011,6451,8241,0709741,1311,3751,2361,4901,2231,0688111,1691,7971,8241,781
Shareholder's Equity-26.2%7,61110,31913,10915,06417,27919,86814,92016,99120,55922,90024,7369,29411,43413,56715,1879,2773,80421.001,0182,2993,170
  Retained Earnings-2.3%-152,141-148,675-145,640-142,358-139,892-137,042-133,234-130,329-126,544-124,018-122,010-119,913-117,650-115,207-113,436-112,026-110,243-109,423-107,718-105,652-104,010
  Additional Paid-In Capital0.5%159,752159,002158,732157,427157,148156,888148,281147,447147,229147,042146,869129,332129,207128,896128,745121,427114,173109,572108,845108,076107,284
Shares Outstanding4.2%2,5972,4932,4842,2992,2971,8131,5491,5421,4541,5391,2831,5421,209--------
Minority Interest--------142-141-141-138-138-136-135-133-132-132-129-128-126-126-122
Float------13,200---58,900---16,200---4,500---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations12.1%-2,377-2,704-2,482-2,946-1,951-2,878-2,728-3,099-2,718-1,878-2,071-2,238-2,197-1,226-1,101-1,620-1,256-1,073-1,247-1,397-1,086
  Share Based Compensation122.8%57325725026026331421522820120112015037816784.0088.00103327327374345
Cashflow From Investing-30.1%-8.81-6.77-230-11.29-151-739-41.17-212-57.93-40.49-38.37-5.25-31.49-5.33-17.81-3.60-28.08-119-886*--
Cashflow From Financing1899.5%177-9.841,078-2.64-1.888,300619-10.64-13.56-28.1317,420-26.14-66.01-16.137,2377,1704,557-514-87.15401833

AEMD Income Statement

2023-12-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended9 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
OPERATING EXPENSES    
Professional fees$ 668,586$ 729,665$ 2,778,335$ 2,575,496
Payroll and related expenses1,919,3051,048,7614,233,9703,191,402
General and administrative979,1971,071,3273,138,2893,653,832
Total operating expenses3,567,0882,849,75310,150,5949,420,730
OPERATING LOSS(3,567,088)(2,849,753)(10,150,594)(9,420,730)
OTHER EXPENSE/(INCOME)    
Loss on dissolution of subsidiary000142,121
Interest and Other Income(100,967)0(367,838)0
NET LOSS(3,466,121)(2,849,753)(9,782,756)(9,562,851)
OTHER COMPREHENSIVE INCOME7,95104,5220
COMPREHENSIVE LOSS$ (3,458,170)$ (2,849,753)$ (9,778,234)$ (9,562,851)

AEMD Balance Sheet

2023-12-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2023
Mar. 31, 2023
Current assets  
Cash$ 7,972,012$ 14,532,943
Prepaid expenses and other current assets277,321557,623
Total current assets8,249,33315,090,566
Property and equipment, net1,113,8801,144,004
Right-of-use lease asset, net951,4661,151,909
Patents, net1,2381,650
Restricted cash87,50687,506
Deposits33,30533,305
Total assets10,436,72817,508,940
Current liabilities  
Accounts payable693,154432,890
Due to related parties656,045214,221
Lease liability, current portion285,095269,386
Other current liabilities466,329588,592
Total current liabilities2,100,6231,505,089
Lease liability, less current portion724,848939,642
Total liabilities2,825,4712,444,731
Stockholders’ Equity  
Common stock, par value $0.001 per share; 60,000,000 shares authorized as of December 31, 2023 and March 31, 2023; 2,596,538 and 2,299,259 shares issued and outstanding as of December 31, 2023 and March 31, 2023, respectively2,5962,299
Additional paid-in capital159,751,591157,426,606
Accumulated other comprehensive loss(1,619)(6,141)
Accumulated deficit(152,141,311)(142,358,555)
Total stockholders’ equity7,611,25715,064,209
Total liabilities and stockholders’ equity$ 10,436,728$ 17,508,940
AEMD
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.
 CEO
 WEBSITEwww.aethlonmedical.com
 EMPLOYEES15

Aethlon Medical Inc Frequently Asked Questions


What is the ticker symbol for Aethlon Medical Inc? What does AEMD stand for in stocks?

AEMD is the stock ticker symbol of Aethlon Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aethlon Medical Inc (AEMD)?

As of Thu Feb 22 2024, market cap of Aethlon Medical Inc is 4.48 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AEMD stock?

You can check AEMD's fair value in chart for subscribers.

What is the fair value of AEMD stock?

You can check AEMD's fair value in chart for subscribers. The fair value of Aethlon Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aethlon Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AEMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aethlon Medical Inc a good stock to buy?

The fair value guage provides a quick view whether AEMD is over valued or under valued. Whether Aethlon Medical Inc is cheap or expensive depends on the assumptions which impact Aethlon Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AEMD.

What is Aethlon Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, AEMD's PE ratio (Price to Earnings) is -0.37 and Price to Sales (PS) ratio is 1.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AEMD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Aethlon Medical Inc's stock?

In the past 10 years, Aethlon Medical Inc has provided -0.356 (multiply by 100 for percentage) rate of return.